Bioburden Testing

Bioburden Testing


:

Global Bioburden Testing Market to Reach $2.1 Billion by 2030
The global market for Bioburden Testing estimated at US$981.8 Million in the year 2023, is expected to reach US$2.1 Billion by 2030, growing at a CAGR of 9.8% over the period 2023-2030. Bioburden Testing Consumables, one of the segments analyzed in the report, is expected to record 10.2% CAGR and reach US$1.3 Billion by the end of the analysis period. Growth in the Bioburden Testing Instrument segment is estimated at 8.9% CAGR for the next 8-year period.

The U.S. Market is Estimated at $298.1 Million, While China is Forecast to Grow at 9.2% CAGR
The Bioburden Testing market in the U.S. is estimated at US$298.1 Million in the year 2023. China, the world`s second largest economy, is forecast to reach a projected market size of US$356.5 Million by the year 2030 trailing a CAGR of 9.2% over the analysis period 2023 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 8.6% and 8.2% respectively over the 2023-2030 period. Within Europe, Germany is forecast to grow at approximately 7.1% CAGR.

Introducing Our Exciting New Report Features for 2024
» Full access to influencer engagement stats
» Free access to our digital archives & "MarketGlass" research platform. Our proprietary MarketGlass platform is fully enabled to unlock creativity and market knowledge of domain experts worldwide in a cohesive and collaborative manner. Our state-of-art tools bring world class market perspectives while protecting participants` privacy and identity. Numbers, statistics and market narrative in the report are based on fully curated insights shared by domain experts and influencers in this space.
» Opportunity to engage with interactive questionnaires that come with real-time data simulator tools & bespoke report generation capabilities
» Full client access to peer collaborative and interactive platform for cross-enterprise smart exchange of ideas
» Complimentary report updates for one year
» Competitor coverage with global market shares of major players
» Player market presence analysis (Strong/Active/Niche/Trivial) across multiple geographies
» Access to curated YouTube video transcripts of domain experts/influencer interviews, podcasts, press statements and event keynotes

What to Expect from the Global Economy in 2024
Edgy geopolitics, and economic instability caused by monetary policy tightening and ensuing higher interest rates will create a tumultuous landscape for 2024. Several factors will continue to exert pressure on the path to recovery including hostilities in the Middle East and increasingly common climate disasters. Among the risks, several positives are also taking shape such as growing signs of disinflation and easing of anxiety over stubborn inflation, supply chain normalization and price moderation despite volatility in energy costs. Elections across several G21 jurisdictions, notably in India and the United States, will have potential ramifications for capital flows and investment strategies. While India emerges as a compelling destination in the global investment landscape, U.S, based tech firms will continue to dominate, fueled by a dynamic ecosystem of talent and capital. Tech opportunities in Silicon Valley and beyond remain attractive for investors seeking high-growth prospects supported largely by a resilient albeit slowing domestic economy and conducive regulatory environment. Europe will continue to battle tight monetary policy and recession risks with U.K. having the most challenging outlook and running the greatest risk of recession in 2024. China remains a wild card with hope for growth in the country underpinned by government spending and improvements in consumer spending. The volatile environment will offer both opportunities and challenges for investors and businesses alike. Embracing volatility as a catalyst for growth together with agility and strategic foresight in navigating investment decisions will remain important for survival.

Select Competitors (Total 41 Featured) -
  • Advanced Bioscience Laboratories, Inc.
  • Becton, Dickinson and Company
  • Biotech Testing Services
  • BTTG
  • C.G. Laboratories
  • Charles River Laboratories International, Inc.
  • Invetech Pty., Ltd.
  • North American Science Associates, LLC
  • Pacific Biolabs
  • SGS SA
Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.


I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Influencer Market Insights
Impact of Covid-19 and a Looming Global Recession
Bioburden Testing – Global Key Competitors Percentage Market Share in 2024 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
Technological Innovations in Microbial Detection Propel Advancements in Bioburden Testing
Increasing Focus on Patient Safety Expands Addressable Market Opportunity for Bioburden Testing
Here`s How Automation in Testing Labs Strengthens Business Case for Bioburden Testing Adoption
Growing Demand for Rapid and Accurate Testing Drives Adoption of Advanced Bioburden Testing Techniques
Expansion of Pharmaceutical and Medical Device Manufacturing Spurs Growth in Bioburden Testing
Innovation in Point-of-Care Testing Technologies Accelerates Demand for Bioburden Testing Solutions
Rising Use of Bioburden Testing in Food and Beverage Industry Expands Market Reach
Increasing Adoption of Bioburden Testing in Contract Research Organizations (CROs) Propels Market Growth
Shift Towards Single-Use Technologies in Bioprocessing Generates Demand for Bioburden Testing
4. GLOBAL MARKET PERSPECTIVE
TABLE 1: World Bioburden Testing Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
TABLE 2: World Recent Past, Current & Future Analysis for Bioburden Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 3: World Historic Review for Bioburden Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 4: World 16-Year Perspective for Bioburden Testing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2024 & 2030
TABLE 5: World Recent Past, Current & Future Analysis for Consumables by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 6: World Historic Review for Consumables by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 7: World 16-Year Perspective for Consumables by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
TABLE 8: World Recent Past, Current & Future Analysis for Instrument by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 9: World Historic Review for Instrument by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 10: World 16-Year Perspective for Instrument by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
TABLE 11: World Recent Past, Current & Future Analysis for Aerobic Count Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 12: World Historic Review for Aerobic Count Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 13: World 16-Year Perspective for Aerobic Count Testing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
TABLE 14: World Recent Past, Current & Future Analysis for Anaerobic Count Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 15: World Historic Review for Anaerobic Count Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 16: World 16-Year Perspective for Anaerobic Count Testing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
TABLE 17: World Recent Past, Current & Future Analysis for Fungi / Mold Count Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 18: World Historic Review for Fungi / Mold Count Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 19: World 16-Year Perspective for Fungi / Mold Count Testing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
TABLE 20: World Recent Past, Current & Future Analysis for Spore Count Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 21: World Historic Review for Spore Count Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 22: World 16-Year Perspective for Spore Count Testing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
TABLE 23: World Recent Past, Current & Future Analysis for Pharma & Biotech Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 24: World Historic Review for Pharma & Biotech Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 25: World 16-Year Perspective for Pharma & Biotech Companies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
TABLE 26: World Recent Past, Current & Future Analysis for Medical Device Manufacturers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 27: World Historic Review for Medical Device Manufacturers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 28: World 16-Year Perspective for Medical Device Manufacturers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
TABLE 29: World Recent Past, Current & Future Analysis for Contract Manufacturing Organizations by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 30: World Historic Review for Contract Manufacturing Organizations by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 31: World 16-Year Perspective for Contract Manufacturing Organizations by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
TABLE 32: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 33: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 34: World 16-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
III. MARKET ANALYSIS
UNITED STATES
Bioburden Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
TABLE 35: USA Recent Past, Current & Future Analysis for Bioburden Testing by Product - Consumables and Instrument - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 36: USA Historic Review for Bioburden Testing by Product - Consumables and Instrument Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 37: USA 16-Year Perspective for Bioburden Testing by Product - Percentage Breakdown of Value Sales for Consumables and Instrument for the Years 2014, 2024 & 2030
TABLE 38: USA Recent Past, Current & Future Analysis for Bioburden Testing by Test Type - Aerobic Count Testing, Anaerobic Count Testing, Fungi / Mold Count Testing and Spore Count Testing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 39: USA Historic Review for Bioburden Testing by Test Type - Aerobic Count Testing, Anaerobic Count Testing, Fungi / Mold Count Testing and Spore Count Testing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 40: USA 16-Year Perspective for Bioburden Testing by Test Type - Percentage Breakdown of Value Sales for Aerobic Count Testing, Anaerobic Count Testing, Fungi / Mold Count Testing and Spore Count Testing for the Years 2014, 2024 & 2030
TABLE 41: USA Recent Past, Current & Future Analysis for Bioburden Testing by End-Use - Pharma & Biotech Companies, Medical Device Manufacturers, Contract Manufacturing Organizations and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 42: USA Historic Review for Bioburden Testing by End-Use - Pharma & Biotech Companies, Medical Device Manufacturers, Contract Manufacturing Organizations and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 43: USA 16-Year Perspective for Bioburden Testing by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Medical Device Manufacturers, Contract Manufacturing Organizations and Other End-Uses for the Years 2014, 2024 & 2030
CANADA
TABLE 44: Canada Recent Past, Current & Future Analysis for Bioburden Testing by Product - Consumables and Instrument - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 45: Canada Historic Review for Bioburden Testing by Product - Consumables and Instrument Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 46: Canada 16-Year Perspective for Bioburden Testing by Product - Percentage Breakdown of Value Sales for Consumables and Instrument for the Years 2014, 2024 & 2030
TABLE 47: Canada Recent Past, Current & Future Analysis for Bioburden Testing by Test Type - Aerobic Count Testing, Anaerobic Count Testing, Fungi / Mold Count Testing and Spore Count Testing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 48: Canada Historic Review for Bioburden Testing by Test Type - Aerobic Count Testing, Anaerobic Count Testing, Fungi / Mold Count Testing and Spore Count Testing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 49: Canada 16-Year Perspective for Bioburden Testing by Test Type - Percentage Breakdown of Value Sales for Aerobic Count Testing, Anaerobic Count Testing, Fungi / Mold Count Testing and Spore Count Testing for the Years 2014, 2024 & 2030
TABLE 50: Canada Recent Past, Current & Future Analysis for Bioburden Testing by End-Use - Pharma & Biotech Companies, Medical Device Manufacturers, Contract Manufacturing Organizations and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 51: Canada Historic Review for Bioburden Testing by End-Use - Pharma & Biotech Companies, Medical Device Manufacturers, Contract Manufacturing Organizations and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 52: Canada 16-Year Perspective for Bioburden Testing by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Medical Device Manufacturers, Contract Manufacturing Organizations and Other End-Uses for the Years 2014, 2024 & 2030
JAPAN
Bioburden Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
TABLE 53: Japan Recent Past, Current & Future Analysis for Bioburden Testing by Product - Consumables and Instrument - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 54: Japan Historic Review for Bioburden Testing by Product - Consumables and Instrument Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 55: Japan 16-Year Perspective for Bioburden Testing by Product - Percentage Breakdown of Value Sales for Consumables and Instrument for the Years 2014, 2024 & 2030
TABLE 56: Japan Recent Past, Current & Future Analysis for Bioburden Testing by Test Type - Aerobic Count Testing, Anaerobic Count Testing, Fungi / Mold Count Testing and Spore Count Testing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 57: Japan Historic Review for Bioburden Testing by Test Type - Aerobic Count Testing, Anaerobic Count Testing, Fungi / Mold Count Testing and Spore Count Testing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 58: Japan 16-Year Perspective for Bioburden Testing by Test Type - Percentage Breakdown of Value Sales for Aerobic Count Testing, Anaerobic Count Testing, Fungi / Mold Count Testing and Spore Count Testing for the Years 2014, 2024 & 2030
TABLE 59: Japan Recent Past, Current & Future Analysis for Bioburden Testing by End-Use - Pharma & Biotech Companies, Medical Device Manufacturers, Contract Manufacturing Organizations and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 60: Japan Historic Review for Bioburden Testing by End-Use - Pharma & Biotech Companies, Medical Device Manufacturers, Contract Manufacturing Organizations and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 61: Japan 16-Year Perspective for Bioburden Testing by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Medical Device Manufacturers, Contract Manufacturing Organizations and Other End-Uses for the Years 2014, 2024 & 2030
CHINA
Bioburden Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
TABLE 62: China Recent Past, Current & Future Analysis for Bioburden Testing by Product - Consumables and Instrument - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 63: China Historic Review for Bioburden Testing by Product - Consumables and Instrument Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 64: China 16-Year Perspective for Bioburden Testing by Product - Percentage Breakdown of Value Sales for Consumables and Instrument for the Years 2014, 2024 & 2030
TABLE 65: China Recent Past, Current & Future Analysis for Bioburden Testing by Test Type - Aerobic Count Testing, Anaerobic Count Testing, Fungi / Mold Count Testing and Spore Count Testing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 66: China Historic Review for Bioburden Testing by Test Type - Aerobic Count Testing, Anaerobic Count Testing, Fungi / Mold Count Testing and Spore Count Testing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 67: China 16-Year Perspective for Bioburden Testing by Test Type - Percentage Breakdown of Value Sales for Aerobic Count Testing, Anaerobic Count Testing, Fungi / Mold Count Testing and Spore Count Testing for the Years 2014, 2024 & 2030
TABLE 68: China Recent Past, Current & Future Analysis for Bioburden Testing by End-Use - Pharma & Biotech Companies, Medical Device Manufacturers, Contract Manufacturing Organizations and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 69: China Historic Review for Bioburden Testing by End-Use - Pharma & Biotech Companies, Medical Device Manufacturers, Contract Manufacturing Organizations and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 70: China 16-Year Perspective for Bioburden Testing by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Medical Device Manufacturers, Contract Manufacturing Organizations and Other End-Uses for the Years 2014, 2024 & 2030
EUROPE
Bioburden Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
TABLE 71: Europe Recent Past, Current & Future Analysis for Bioburden Testing by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 72: Europe Historic Review for Bioburden Testing by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 73: Europe 16-Year Perspective for Bioburden Testing by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2024 & 2030
TABLE 74: Europe Recent Past, Current & Future Analysis for Bioburden Testing by Product - Consumables and Instrument - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 75: Europe Historic Review for Bioburden Testing by Product - Consumables and Instrument Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 76: Europe 16-Year Perspective for Bioburden Testing by Product - Percentage Breakdown of Value Sales for Consumables and Instrument for the Years 2014, 2024 & 2030
TABLE 77: Europe Recent Past, Current & Future Analysis for Bioburden Testing by Test Type - Aerobic Count Testing, Anaerobic Count Testing, Fungi / Mold Count Testing and Spore Count Testing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 78: Europe Historic Review for Bioburden Testing by Test Type - Aerobic Count Testing, Anaerobic Count Testing, Fungi / Mold Count Testing and Spore Count Testing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 79: Europe 16-Year Perspective for Bioburden Testing by Test Type - Percentage Breakdown of Value Sales for Aerobic Count Testing, Anaerobic Count Testing, Fungi / Mold Count Testing and Spore Count Testing for the Years 2014, 2024 & 2030
TABLE 80: Europe Recent Past, Current & Future Analysis for Bioburden Testing by End-Use - Pharma & Biotech Companies, Medical Device Manufacturers, Contract Manufacturing Organizations and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 81: Europe Historic Review for Bioburden Testing by End-Use - Pharma & Biotech Companies, Medical Device Manufacturers, Contract Manufacturing Organizations and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 82: Europe 16-Year Perspective for Bioburden Testing by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Medical Device Manufacturers, Contract Manufacturing Organizations and Other End-Uses for the Years 2014, 2024 & 2030
FRANCE
Bioburden Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
TABLE 83: France Recent Past, Current & Future Analysis for Bioburden Testing by Product - Consumables and Instrument - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 84: France Historic Review for Bioburden Testing by Product - Consumables and Instrument Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 85: France 16-Year Perspective for Bioburden Testing by Product - Percentage Breakdown of Value Sales for Consumables and Instrument for the Years 2014, 2024 & 2030
TABLE 86: France Recent Past, Current & Future Analysis for Bioburden Testing by Test Type - Aerobic Count Testing, Anaerobic Count Testing, Fungi / Mold Count Testing and Spore Count Testing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 87: France Historic Review for Bioburden Testing by Test Type - Aerobic Count Testing, Anaerobic Count Testing, Fungi / Mold Count Testing and Spore Count Testing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 88: France 16-Year Perspective for Bioburden Testing by Test Type - Percentage Breakdown of Value Sales for Aerobic Count Testing, Anaerobic Count Testing, Fungi / Mold Count Testing and Spore Count Testing for the Years 2014, 2024 & 2030
TABLE 89: France Recent Past, Current & Future Analysis for Bioburden Testing by End-Use - Pharma & Biotech Companies, Medical Device Manufacturers, Contract Manufacturing Organizations and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 90: France Historic Review for Bioburden Testing by End-Use - Pharma & Biotech Companies, Medical Device Manufacturers, Contract Manufacturing Organizations and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 91: France 16-Year Perspective for Bioburden Testing by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Medical Device Manufacturers, Contract Manufacturing Organizations and Other End-Uses for the Years 2014, 2024 & 2030
GERMANY
Bioburden Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
TABLE 92: Germany Recent Past, Current & Future Analysis for Bioburden Testing by Product - Consumables and Instrument - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 93: Germany Historic Review for Bioburden Testing by Product - Consumables and Instrument Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 94: Germany 16-Year Perspective for Bioburden Testing by Product - Percentage Breakdown of Value Sales for Consumables and Instrument for the Years 2014, 2024 & 2030
TABLE 95: Germany Recent Past, Current & Future Analysis for Bioburden Testing by Test Type - Aerobic Count Testing, Anaerobic Count Testing, Fungi / Mold Count Testing and Spore Count Testing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 96: Germany Historic Review for Bioburden Testing by Test Type - Aerobic Count Testing, Anaerobic Count Testing, Fungi / Mold Count Testing and Spore Count Testing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 97: Germany 16-Year Perspective for Bioburden Testing by Test Type - Percentage Breakdown of Value Sales for Aerobic Count Testing, Anaerobic Count Testing, Fungi / Mold Count Testing and Spore Count Testing for the Years 2014, 2024 & 2030
TABLE 98: Germany Recent Past, Current & Future Analysis for Bioburden Testing by End-Use - Pharma & Biotech Companies, Medical Device Manufacturers, Contract Manufacturing Organizations and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 99: Germany Historic Review for Bioburden Testing by End-Use - Pharma & Biotech Companies, Medical Device Manufacturers, Contract Manufacturing Organizations and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 100: Germany 16-Year Perspective for Bioburden Testing by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Medical Device Manufacturers, Contract Manufacturing Organizations and Other End-Uses for the Years 2014, 2024 & 2030
ITALY
TABLE 101: Italy Recent Past, Current & Future Analysis for Bioburden Testing by Product - Consumables and Instrument - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 102: Italy Historic Review for Bioburden Testing by Product - Consumables and Instrument Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 103: Italy 16-Year Perspective for Bioburden Testing by Product - Percentage Breakdown of Value Sales for Consumables and Instrument for the Years 2014, 2024 & 2030
TABLE 104: Italy Recent Past, Current & Future Analysis for Bioburden Testing by Test Type - Aerobic Count Testing, Anaerobic Count Testing, Fungi / Mold Count Testing and Spore Count Testing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 105: Italy Historic Review for Bioburden Testing by Test Type - Aerobic Count Testing, Anaerobic Count Testing, Fungi / Mold Count Testing and Spore Count Testing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 106: Italy 16-Year Perspective for Bioburden Testing by Test Type - Percentage Breakdown of Value Sales for Aerobic Count Testing, Anaerobic Count Testing, Fungi / Mold Count Testing and Spore Count Testing for the Years 2014, 2024 & 2030
TABLE 107: Italy Recent Past, Current & Future Analysis for Bioburden Testing by End-Use - Pharma & Biotech Companies, Medical Device Manufacturers, Contract Manufacturing Organizations and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 108: Italy Historic Review for Bioburden Testing by End-Use - Pharma & Biotech Companies, Medical Device Manufacturers, Contract Manufacturing Organizations and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 109: Italy 16-Year Perspective for Bioburden Testing by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Medical Device Manufacturers, Contract Manufacturing Organizations and Other End-Uses for the Years 2014, 2024 & 2030
UNITED KINGDOM
Bioburden Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
TABLE 110: UK Recent Past, Current & Future Analysis for Bioburden Testing by Product - Consumables and Instrument - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 111: UK Historic Review for Bioburden Testing by Product - Consumables and Instrument Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 112: UK 16-Year Perspective for Bioburden Testing by Product - Percentage Breakdown of Value Sales for Consumables and Instrument for the Years 2014, 2024 & 2030
TABLE 113: UK Recent Past, Current & Future Analysis for Bioburden Testing by Test Type - Aerobic Count Testing, Anaerobic Count Testing, Fungi / Mold Count Testing and Spore Count Testing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 114: UK Historic Review for Bioburden Testing by Test Type - Aerobic Count Testing, Anaerobic Count Testing, Fungi / Mold Count Testing and Spore Count Testing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 115: UK 16-Year Perspective for Bioburden Testing by Test Type - Percentage Breakdown of Value Sales for Aerobic Count Testing, Anaerobic Count Testing, Fungi / Mold Count Testing and Spore Count Testing for the Years 2014, 2024 & 2030
TABLE 116: UK Recent Past, Current & Future Analysis for Bioburden Testing by End-Use - Pharma & Biotech Companies, Medical Device Manufacturers, Contract Manufacturing Organizations and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 117: UK Historic Review for Bioburden Testing by End-Use - Pharma & Biotech Companies, Medical Device Manufacturers, Contract Manufacturing Organizations and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 118: UK 16-Year Perspective for Bioburden Testing by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Medical Device Manufacturers, Contract Manufacturing Organizations and Other End-Uses for the Years 2014, 2024 & 2030
REST OF EUROPE
TABLE 119: Rest of Europe Recent Past, Current & Future Analysis for Bioburden Testing by Product - Consumables and Instrument - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 120: Rest of Europe Historic Review for Bioburden Testing by Product - Consumables and Instrument Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 121: Rest of Europe 16-Year Perspective for Bioburden Testing by Product - Percentage Breakdown of Value Sales for Consumables and Instrument for the Years 2014, 2024 & 2030
TABLE 122: Rest of Europe Recent Past, Current & Future Analysis for Bioburden Testing by Test Type - Aerobic Count Testing, Anaerobic Count Testing, Fungi / Mold Count Testing and Spore Count Testing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 123: Rest of Europe Historic Review for Bioburden Testing by Test Type - Aerobic Count Testing, Anaerobic Count Testing, Fungi / Mold Count Testing and Spore Count Testing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 124: Rest of Europe 16-Year Perspective for Bioburden Testing by Test Type - Percentage Breakdown of Value Sales for Aerobic Count Testing, Anaerobic Count Testing, Fungi / Mold Count Testing and Spore Count Testing for the Years 2014, 2024 & 2030
TABLE 125: Rest of Europe Recent Past, Current & Future Analysis for Bioburden Testing by End-Use - Pharma & Biotech Companies, Medical Device Manufacturers, Contract Manufacturing Organizations and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 126: Rest of Europe Historic Review for Bioburden Testing by End-Use - Pharma & Biotech Companies, Medical Device Manufacturers, Contract Manufacturing Organizations and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 127: Rest of Europe 16-Year Perspective for Bioburden Testing by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Medical Device Manufacturers, Contract Manufacturing Organizations and Other End-Uses for the Years 2014, 2024 & 2030
ASIA-PACIFIC
Bioburden Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
TABLE 128: Asia-Pacific Recent Past, Current & Future Analysis for Bioburden Testing by Product - Consumables and Instrument - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 129: Asia-Pacific Historic Review for Bioburden Testing by Product - Consumables and Instrument Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 130: Asia-Pacific 16-Year Perspective for Bioburden Testing by Product - Percentage Breakdown of Value Sales for Consumables and Instrument for the Years 2014, 2024 & 2030
TABLE 131: Asia-Pacific Recent Past, Current & Future Analysis for Bioburden Testing by Test Type - Aerobic Count Testing, Anaerobic Count Testing, Fungi / Mold Count Testing and Spore Count Testing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 132: Asia-Pacific Historic Review for Bioburden Testing by Test Type - Aerobic Count Testing, Anaerobic Count Testing, Fungi / Mold Count Testing and Spore Count Testing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 133: Asia-Pacific 16-Year Perspective for Bioburden Testing by Test Type - Percentage Breakdown of Value Sales for Aerobic Count Testing, Anaerobic Count Testing, Fungi / Mold Count Testing and Spore Count Testing for the Years 2014, 2024 & 2030
TABLE 134: Asia-Pacific Recent Past, Current & Future Analysis for Bioburden Testing by End-Use - Pharma & Biotech Companies, Medical Device Manufacturers, Contract Manufacturing Organizations and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 135: Asia-Pacific Historic Review for Bioburden Testing by End-Use - Pharma & Biotech Companies, Medical Device Manufacturers, Contract Manufacturing Organizations and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 136: Asia-Pacific 16-Year Perspective for Bioburden Testing by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Medical Device Manufacturers, Contract Manufacturing Organizations and Other End-Uses for the Years 2014, 2024 & 2030
REST OF WORLD
TABLE 137: Rest of World Recent Past, Current & Future Analysis for Bioburden Testing by Product - Consumables and Instrument - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 138: Rest of World Historic Review for Bioburden Testing by Product - Consumables and Instrument Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 139: Rest of World 16-Year Perspective for Bioburden Testing by Product - Percentage Breakdown of Value Sales for Consumables and Instrument for the Years 2014, 2024 & 2030
TABLE 140: Rest of World Recent Past, Current & Future Analysis for Bioburden Testing by Test Type - Aerobic Count Testing, Anaerobic Count Testing, Fungi / Mold Count Testing and Spore Count Testing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 141: Rest of World Historic Review for Bioburden Testing by Test Type - Aerobic Count Testing, Anaerobic Count Testing, Fungi / Mold Count Testing and Spore Count Testing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 142: Rest of World 16-Year Perspective for Bioburden Testing by Test Type - Percentage Breakdown of Value Sales for Aerobic Count Testing, Anaerobic Count Testing, Fungi / Mold Count Testing and Spore Count Testing for the Years 2014, 2024 & 2030
TABLE 143: Rest of World Recent Past, Current & Future Analysis for Bioburden Testing by End-Use - Pharma & Biotech Companies, Medical Device Manufacturers, Contract Manufacturing Organizations and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 144: Rest of World Historic Review for Bioburden Testing by End-Use - Pharma & Biotech Companies, Medical Device Manufacturers, Contract Manufacturing Organizations and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 145: Rest of World 16-Year Perspective for Bioburden Testing by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Medical Device Manufacturers, Contract Manufacturing Organizations and Other End-Uses for the Years 2014, 2024 & 2030
IV. COMPETITION

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings